BioMarin Pharmaceutical (NASDAQ:BMRN) EVP Sells 5,147 Shares of Company Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) EVP Gregory Friberg sold 5,147 shares of the business’s stock in a transaction dated Wednesday, November 18th. The stock was sold at an average price of $58.81, for a total transaction of $302,695.07. Following the completion of the sale, the executive vice president owned 42,585 shares in the company, valued at approximately $2,504,423.85. This trade represents a 10.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

BioMarin Pharmaceutical Stock Down 0.0%

Shares of NASDAQ:BMRN traded down $0.01 on Thursday, reaching $61.42. The company had a trading volume of 5,206,755 shares, compared to its average volume of 2,142,394. BioMarin Pharmaceutical Inc. has a twelve month low of $49.26 and a twelve month high of $70.98. The company has a quick ratio of 1.32, a current ratio of 2.44 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $11.90 billion, a P/E ratio of -614.20, a P/E/G ratio of 0.78 and a beta of 0.21. The stock has a 50-day moving average price of $58.50 and a 200 day moving average price of $58.52.

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.28. BioMarin Pharmaceutical had a positive return on equity of 5.58% and a negative net margin of 0.52%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.02 billion. During the same period in the previous year, the business posted $0.12 earnings per share. The firm’s revenue for the quarter was up 32.0% compared to the same quarter last year. On average, equities analysts expect that BioMarin Pharmaceutical Inc. will post 2.20 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. HC Wainwright reiterated a “neutral” rating and issued a $60.00 target price on shares of BioMarin Pharmaceutical in a report on Tuesday, November 3rd. Piper Sandler lifted their price objective on BioMarin Pharmaceutical from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 1st. Barclays lifted their target price on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of BioMarin Pharmaceutical in a report on Tuesday, November 3rd. Finally, William Blair upgraded BioMarin Pharmaceutical to a “hold” rating in a research report on Wednesday, September 23rd. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.22.

Check Out Our Latest Analysis on BMRN

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several institutional investors have recently modified their holdings of BMRN. Parkside Financial Bank & Trust boosted its holdings in shares of BioMarin Pharmaceutical by 70.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 187 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its stake in shares of BioMarin Pharmaceutical by 0.5% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 40,117 shares of the biotechnology company’s stock valued at $2,407,000 after buying an additional 200 shares in the last quarter. North Dakota State Investment Board grew its position in shares of BioMarin Pharmaceutical by 3.9% during the third quarter. North Dakota State Investment Board now owns 5,872 shares of the biotechnology company’s stock worth $352,000 after purchasing an additional 218 shares in the last quarter. Signaturefd LLC raised its position in shares of BioMarin Pharmaceutical by 16.7% during the third quarter. Signaturefd LLC now owns 2,316 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 331 shares during the last quarter. Finally, Bessemer Group Inc. boosted its holdings in shares of BioMarin Pharmaceutical by 0.5% during the 3rd quarter. Bessemer Group Inc. now owns 90,036 shares of the biotechnology company’s stock valued at $5,401,000 after purchasing an additional 447 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

(Get Free Report)

BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options. The company’s marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe.

Further Reading

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.